Developments in Psychedelic Regulation for COMP360

Jama Pitman, an advisor at Rose Hill Life Sciences, discussed the regulatory landscape surrounding psychedelic drug development, with particular attention to Compass Pathways' COMP360 (synthetic psilocybin) and the emerging US Food and Drug Administration (FDA) approval pathways relevant to this drug class.

Pitman described the national priority review voucher pilot program, initiated by the FDA commissioner, as a mechanism designed to accelerate regulatory review from the traditional 6-to-10-month timeline down to 1 to 2 months. She noted that when the inaugural cohort of 9 vouchers was issued recently, COMP360 was notably absent, having been dropped from the final list approved by the Department of Health and Human Services.¹ Pitman contextualized this setback by emphasizing that several other FDA expedited pathways remained available, including breakthrough therapy designation, which Compass Pathways had already received for COMP360, and standard priority review, which compresses review to 6 months.² She expressed positivity that the first psychedelic to reach the approval stage may qualify for priority review.

Pitman addressed several clinical and operational challenges inherent to psychedelic drug development. She highlighted functional unblinding as a significant methodological concern, noting that patients randomized to placebo arms often recognized their assignment given the absence of psychoactive effects, potentially biasing self-reported symptom outcomes. She also raised the difficulty of disentangling drug-specific effects from concurrent psychotherapy, an issue the FDA had taken a clear position on in terms of trial design requirements.

Regarding post-approval administration, Pitman emphasized that psychedelics would require a risk evaluation and mitigation strategy, including certified prescribers, trained facilitators present during the approximately 6-hour drug administration session, and structured post-experience integration sessions. She also addressed the scheduling barrier, noting that the Drug Enforcement Administration forwarded a petition in August 2025 to reschedule psychedelics from schedule I to schedule II, with subsequent state-level legislative processes anticipated to follow federal action.

Pitman concluded by expressing measured optimism, arguing that sufficient scientific evidence had accumulated to legitimize psychedelics as a serious area of medicine, and that the treatment landscape across both psychiatric and neurological conditions stood to change substantially following the first approval.

Ms Pitman is a strategic advisor at Rose Hill Life Sciences.

References

1. FDA awards first-ever national priority vouchers to nine sponsors. Press release. October 16, 2025. Accessed February 24, 2026. https://www.fda.gov/news-events/press-announcements/fda-awards-first-ever-national-priority-vouchers-nine-sponsors

2. COMPASS Pathways receives FDA Breakthrough Therapy designation for psilocybin therapy for treatment-resistant depression. Press release. October 23, 2018. Accessed February 24, 2026. https://ir.compasspathways.com/News--Events-/news/news-details/2018/COMPASS-Pathways-receives-FDA-Breakthrough-Therapy-designation-for-psilocybin-therapy-for-treatment-resistant-depression/default.aspx